Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
Type:
Grant
Filed:
May 7, 2021
Date of Patent:
January 3, 2023
Assignee:
Synthetic Biologics, Inc.
Inventors:
Andrew Bristol, Michael Kaleko, Steven Hubert
Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
Abstract: Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
May 24, 2022
Assignee:
Synthetic Biologics, Inc.
Inventors:
Michael Kaleko, Christian Furlan Freguia, Sheila Connelly
Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
June 15, 2021
Assignee:
Synthetic Biologics, Inc.
Inventors:
Andrew Bristol, Michael Kaleko, Steven Hubert
Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
Type:
Grant
Filed:
July 17, 2018
Date of Patent:
April 27, 2021
Assignee:
Synthetic Biologics, Inc.
Inventors:
Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
Type:
Application
Filed:
June 29, 2020
Publication date:
January 21, 2021
Applicants:
CEDARS-SINAI MEDICAL CENTER, Synthetic Biologics, Inc.
Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
Type:
Application
Filed:
June 21, 2017
Publication date:
December 17, 2020
Applicants:
Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
November 10, 2020
Assignee:
Synthetic Biologics, Inc.
Inventors:
Andrew Bristol, Michael Kaleko, Sheila Connelly
Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
Type:
Application
Filed:
April 27, 2020
Publication date:
October 15, 2020
Applicants:
Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
Inventors:
Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
October 6, 2020
Assignee:
Synthetic Biologics, Inc.
Inventors:
Michael Kaleko, Sheila Connelly, Vincent John Wacher
Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
August 11, 2020
Assignees:
Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
January 7, 2020
Assignees:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
Inventors:
Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
Type:
Application
Filed:
May 7, 2019
Publication date:
October 31, 2019
Applicants:
Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
Inventors:
Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Abstract: The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
April 9, 2019
Assignee:
SYNTHETIC BIOLOGICS, INC.
Inventors:
Pertti Koski, Ulla Airaksinen, Katja Valimaki